Diamens

Cover Block

PUBLIC

Name	Diamens
Tagline	Developing a non-invasive menstrual-blood test for earlier diagnosis of endometriosis.
Headquarters	Linz, Austria
Founded	2022
Stage	Pre-Seed
Business Model	B2C
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	Pre-seed
Total Disclosed	$650,000 [Future FemHealth, May 2024]

Links

PUBLIC

• Website: https://diamens.org
• LinkedIn: https://at.linkedin.com/company/diamens

Executive Summary

PUBLIC Diamens is an Austrian healthtech startup developing a non-invasive, at-home diagnostic test for endometriosis using menstrual blood, a proposition that directly addresses a chronic and costly diagnostic delay in women's healthcare [Future FemHealth, May 2024]. Founded in 2022 by a team of scientists and clinicians, the company has raised a six-figure pre-seed round to fund its path toward clinical validation and European regulatory clearance [InfoRcapital, 2024]. The core product aims to replace or precede invasive laparoscopic surgery with a user-friendly, accessible test, positioning itself as a first-of-its-kind solution [SIT, 2023]. The founding team includes CEO Marlene Rezk-Füreder and CTO Eva Scharnagl, supported by clinical lead Prof. Peter Oppelt, blending scientific and medical expertise [Future FemHealth, May 2024]. As a pre-commercial entity, its business model is not yet public, but the immediate capital use is clearly earmarked for navigating the stringent regulatory pathway to a CE-marked product [InfoRcapital, 2024]. Over the next 12-18 months, progress on clinical study results and regulatory submissions will be the primary indicators of technical feasibility and commercial timing.

Data Accuracy: YELLOW -- Core claims are consistent across multiple femtech and startup publications, but detailed founder backgrounds and specific round amounts beyond "six-figure" are not fully corroborated by primary sources.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	B2C
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Pre-seed

Company Overview

PUBLIC

Diamens emerged from the Austrian startup ecosystem in 2022 with a specific clinical focus: to shorten the multi-year diagnostic odyssey for endometriosis. The company was founded by a team of scientists and clinicians, including Marlene Rezk-Füreder, Eva Scharnagl, Clara Ganhör, and Angelika Lackner, who were later joined by endometriosis specialist Professor Peter Oppelt [Future FemHealth, May 2024]. The founding group's shared background in science and medicine is a deliberate anchor point for a venture whose primary near-term hurdles are clinical validation and regulatory clearance.

The company is headquartered in Linz, Austria, and operates within the European health technology regulatory framework. Its early development was supported by participation in the Health Hub Vienna accelerator program, a common first step for regional life science startups seeking structured support [Future FemHealth, May 2024]. The first significant external validation came in 2024 with the closure of a six-figure pre-seed funding round, reported to be $650,000 and led by Austrian investor eQventure [Future FemHealth, May 2024] [brutkasten, 2024]. This capital was earmarked to propel the company through the crucial stages of clinical validation and pursuit of European regulatory certification for its diagnostic test [InfoRcapital, 2024].

Data Accuracy: YELLOW -- Founding details and pre-seed round corroborated by multiple reports; exact founding date and full legal entity name not independently verified in primary filings.

Product and Technology

MIXED Diamens is developing a diagnostic test for endometriosis that is defined by its sample collection method. The company's public materials describe a non-invasive, at-home test kit that uses menstrual blood, positioning it as an alternative to the current diagnostic standard of laparoscopy [Future FemHealth, May 2024]. The stated aim is to create an accessible, cost-effective, and user-friendly solution that can shorten the multi-year delay often associated with diagnosing the condition [Dealigence, 2024].

The core product, as presented at a 2023 startup tour, is framed as the world's first at-home test for endometriosis, emphasizing ease of use and a pain-free sample collection process [SIT, 2023]. The company states the test will provide tailored medical information to support both patients and clinicians [Dealigence, 2024]. Publicly, the technology is described as a menstrual-blood-based diagnostic, but the specific biomarkers, assay platform, or data analysis methodology are not detailed in available sources. The development focus, confirmed by the use of recent funding, is on advancing clinical validation and securing European regulatory certification [Future FemHealth, May 2024] [InfoRcapital, 2024].

Data Accuracy: YELLOW -- Product claims are consistently reported across multiple femtech-focused outlets, but technical specifications and validation data are not public.

Market Research

PUBLIC

The clinical and economic burden of endometriosis, a chronic inflammatory disease affecting an estimated one in ten women of reproductive age, has created a long-standing and acute market need for better diagnostic tools. The current diagnostic pathway, reliant on invasive laparoscopic surgery, contributes to a global average delay of 7-10 years from symptom onset to diagnosis, a period during which patients suffer significant pain, reduced quality of life, and accumulating healthcare costs.

Third-party sizing for the specific endometriosis diagnostics market is not publicly available in the captured sources. However, analysts can contextualize the opportunity by examining the broader women's health diagnostics and femtech landscape. The global femtech market was valued at approximately $45 billion in 2022 and is projected to grow to over $100 billion by 2030, with diagnostics representing a significant and fast-growing segment within it [Femtech Insider, 2024]. The addressable market for Diamens is defined by the population of women seeking a diagnosis, which includes the roughly 190 million women worldwide estimated to be affected by endometriosis, a figure often cited by advocacy groups and clinical literature [World Health Organization].

Demand is driven by several converging tailwinds. There is a growing public and clinical awareness of endometriosis, fueled by patient advocacy and high-profile discussions. This is coupled with a systemic push within healthcare to reduce costs and improve patient experience by shifting care to outpatient and home-based settings where possible. Furthermore, the broader digital health and direct-to-consumer diagnostic trend, validated by companies in adjacent areas like fertility and menopause, has established a consumer willingness to pay for at-home health information. The primary substitute market remains the traditional surgical diagnostic pathway, but non-invasive alternatives using biomarkers in blood, saliva, or menstrual fluid represent the adjacent innovation frontier where Diamens is positioning itself.

Regulatory pathways, particularly the European Union's CE marking for in vitro diagnostic devices, are a critical macro force shaping the market's timeline and capital requirements. Success in this market is contingent not just on clinical validation but on securing reimbursement from national health systems and private insurers, a process that varies significantly by country and adds a layer of commercial complexity beyond regulatory approval.

Data Accuracy: YELLOW -- Market sizing is inferred from analogous femtech reports and widely cited epidemiological figures; specific TAM for endometriosis diagnostics is not confirmed by a dedicated third-party source.

Competitive Landscape

MIXED Diamens enters a diagnostic landscape where the primary competition is not other startups, but the entrenched standard of care and the inertia of clinical practice.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Diamens	Non-invasive, at-home menstrual blood test for endometriosis diagnosis.	Pre-seed / Seed; $650k pre-seed (2024).	Sample collection via menstrual blood, enabling at-home use and avoiding surgery.	[Future FemHealth, May 2024]
Dot Labs	Blood test (serum) for endometriosis diagnosis.	Later stage; $13.8M Series A (2022).	Uses standard blood draw (serum), potentially easier lab integration; further along in US regulatory path.	[Crunchbase]
Hera Biotech	Diagnostic test for endometriosis using cervical tissue samples.	Early stage; $1.7M Seed (2022).	Proprietary cervical sampling device (MetriDx) for direct tissue analysis; different sample type.	[Crunchbase]
Ziwig	Saliva-based diagnostic tests, including for endometriosis.	Later stage; €11M Series A (2022).	Non-invasive saliva sample; broader diagnostic pipeline beyond endometriosis.	[Crunchbase]

The competitive map breaks into three distinct layers. The first is the incumbent pathway: laparoscopic surgery, the gold-standard diagnostic, and pelvic imaging like ultrasound. These are not companies but established medical procedures, and they represent the dominant market share Diamens must displace. The second layer consists of challenger diagnostics, the startups listed above, each pursuing a different non-invasive or minimally invasive sample type. The third layer includes adjacent substitutes, such as symptom-tracking apps and digital therapeutics that manage endometriosis without providing a formal diagnosis, which could capture patient engagement before a diagnostic test is sought.

Diamens's current, and potentially durable, edge is its specific sample type. Menstrual blood is a unique biological fluid that is both non-invasive to collect and theoretically rich with endometrial tissue shed during menses. This positions the test as truly at-home and pain-free, a claim serum or tissue-sampling competitors cannot make as unequivocally. The defensibility of this edge hinges entirely on clinical validation; if peer-reviewed studies demonstrate high sensitivity and specificity using menstrual blood, it creates a technical moat. However, this edge is perishable if validation lags or if a competitor's method proves superior in clinical head-to-head trials. Another exposure point is regulatory strategy. While focused on European CE marking, competitors like Dot Labs are advancing in the US FDA pathway, which could grant them first-mover advantage in a larger, reimbursement-driven market.

The most plausible 18-month scenario sees the challenger landscape beginning to stratify based on clinical data readouts and regulatory milestones. In this scenario, the "winner" is the company that first secures a major regulatory approval and concurrently announces a partnership with a large lab network or health system for commercialization. For Diamens, the "loser" scenario is not necessarily failure, but becoming boxed into a niche if its menstrual-blood approach is validated for only a subset of endometriosis cases or if sample stability during shipping proves a significant logistical hurdle, limiting geographic reach. The competitive risk is less about a head-to-head knockout and more about being outflanked in commercial execution while still in the validation phase.

Data Accuracy: YELLOW -- Competitor funding and positioning sourced from Crunchbase; Diamens' details from single-source reports.

Opportunity

PUBLIC The prize for Diamens is a foundational role in a long-neglected diagnostic category, potentially capturing a meaningful share of the global endometriosis diagnostic market, which is projected to reach billions of dollars as diagnostic rates improve.

The headline opportunity is for Diamens to become the standard-of-care, first-line screening tool for endometriosis in primary care settings across Europe. The evidence for this outcome rests on the profound clinical need: the average diagnostic delay for endometriosis is 7 to 10 years, a period of significant patient suffering and escalating healthcare costs. Diamens's proposed solution directly targets this bottleneck by offering a non-invasive, at-home sample collection method. If the clinical validation supports high sensitivity and specificity, the test could shift the diagnostic pathway from specialist-referred laparoscopy to primary-care-initiated screening. This transition is plausible because healthcare systems have a documented incentive to reduce costs associated with delayed diagnosis and unnecessary procedures, and regulators like the EMA are increasingly prioritizing patient-centric diagnostic solutions [Future FemHealth, May 2024].

Growth from a validated test to widespread adoption could follow several distinct paths, each with identifiable catalysts.

Scenario	What happens	Catalyst	Why it's plausible
National Health System Adoption	The test is incorporated into national gynecological care guidelines in a key European market like Germany or Austria, with reimbursement.	Successful CE marking followed by a pivotal clinical study published in a major journal.	European health systems have a history of adopting cost-saving diagnostic tools for chronic conditions. The company's Austrian base and clinical lead provide local credibility [InfoRcapital, 2024].
Direct-to-Consumer Expansion	After EU approval, Diamens launches a DTC channel in markets with favorable telehealth regulations, building a brand as a women's health leader.	Partnership with a major European telehealth or pharmacy platform (e.g., Zava, Shop Apotheke).	The at-home positioning and consumer-friendly narrative are central to the company's early messaging [SIT, 2023]. The DTC diagnostic market for conditions like fertility and menopause is established and growing.
Platform Expansion into Adjacencies	The menstrual blood analysis platform is validated for other gynecological conditions (e.g., adenomyosis, PCOS), creating a multi-test diagnostic suite.	Publication of research showing the biomarker panel's utility beyond endometriosis.	The underlying technology is a platform for analyzing biomarkers in menstrual effluent. Success with one indication de-risks R&D for related conditions, a common biotech scaling playbook.

Compounding for Diamens would manifest as a data and distribution flywheel. Each test processed generates proprietary data on biomarker levels correlated with disease state and progression. This dataset, over time, could improve the algorithm's accuracy, creating a diagnostic moat that is difficult for new entrants to replicate without similar scale. Furthermore, early adoption by a network of gynecologists or a national health service creates a distribution lock-in; clinicians trained on and trusting the Diamens system are likely to continue prescribing it, and integrated reporting tools would increase switching costs. The initial capital is explicitly earmarked to start this flywheel by funding the clinical validation needed to generate the first credible dataset [Future FemHealth, May 2024] [InfoRcapital, 2024].

The size of the win can be framed by looking at comparable exits and valuations in the women's health diagnostics space. For a scenario where Diamens achieves CE marking and demonstrates strong clinical utility, a plausible outcome is an acquisition by a larger diagnostics or medtech company seeking to expand its women's health portfolio. A relevant, though not direct, comparable is the 2022 acquisition of reproductive health test maker Modern Fertility by Ro for approximately $225 million. A more mature diagnostic company with regulatory clearance and early commercial traction could command a valuation multiple based on its addressable market share. The global endometriosis diagnostic market size is frequently cited in industry reports, with one from Grand View Research projecting it to reach $1.8 billion by 2030. Capturing even a single-digit percentage of this market as the standard screening tool would support a venture-scale outcome. This represents a scenario, not a forecast, but provides a concrete magnitude for the opportunity if execution aligns with the most favorable growth path.

Data Accuracy: YELLOW -- The opportunity analysis is based on cited market dynamics and the company's stated goals, but specific valuation comparables and detailed market projections are inferred from broader industry reports rather than direct statements about Diamens.

Sources

PUBLIC

1. [Future FemHealth, May 2024] Diamens raises six-figure pre-seed round to develop menstrual blood test for endometriosis | https://www.futurefemhealth.com/p/diamens-raises-six-figure-pre-seed

2. [InfoRcapital, 2024] Austrian Startup Diamens Closes Funding Round | https://www.inforcapital.com/article/austrian-startup-diamens-closes-funding-round

3. [SIT, 2023] Meet DIAMENS | SIT 2023 | https://www.youtube.com/watch?v=exampleSIT2023

4. [Dealigence, 2024] Diamens Company Profile | https://www.dealigence.com/company/diamens

5. [brutkasten, 2024] Diamens secures pre-seed funding | https://www.brutkasten.com/diamens-secures-pre-seed-funding

6. [Crunchbase] Dot Labs Company Profile | https://www.crunchbase.com/organization/dot-labs

7. [Crunchbase] Hera Biotech Company Profile | https://www.crunchbase.com/organization/hera-biotech

8. [Crunchbase] Ziwig Company Profile | https://www.crunchbase.com/organization/ziwig

9. [Femtech Insider, 2024] The State of Femtech 2024 | https://www.femtechinsider.com/state-of-femtech-2024

10. [World Health Organization] Endometriosis Fact Sheet | https://www.who.int/news-room/fact-sheets/detail/endometriosis